Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-ND phase 3 study of daprodustat versus darbepoetin alfa in non-dialysis chronic kidney disease anemia
MOH_2017-03-28_000279Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jul 2016
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anemia of renal disease comparing Daprodustat with Darbepoetin alfa (2 arms). Primary endpoints: Cardiovascular safety and Hemoglobin efficacy. Started Jul 2016; status: recruiting.
02
Drugs
daprodustatdarbepoetin alfa
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on MOH_2017-03-28_000279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-28_000279.